Next 10 |
home / stock / lgvn / lgvn articles
Richard Kender, retired SVP of Business Development and Corporate Licensing for Merck & Co., Inc., has been appointed to the Longeveron Board...
MIAMI, April 25, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing regenerative medicine...
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Wednesday. The Dow traded up 0.04% to...
U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 100 points on Wednesday. The Dow traded down 0.32% to 37,6...
U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday. The Dow traded down 0.64% to 37,741.18 whi...
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the P...
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 38,11...
Longeveron Inc. (NASDAQ:LGVN) shares are trading higher Monday following insider buys from multiple company executives. Here's a look at what&...
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday. The Dow traded up 0.89% to 38,321.05 while...
News, Short Squeeze, Breakout and More Instantly...
Longeveron Inc. Company Name:
LGVN Stock Symbol:
NASDAQ Market:
Phase 2b clinical trial evaluating Lomecel-B TM in rare pediatric disease HLHS on track for completing enrollment by end of 2024 Data from Phase 2a clinical trial evaluating Lomecel-B TM in Alzheimer’s Disease selected for Featured Research Oral Presentation at 2024 Alzheimer...
Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, is reporting changes on its board of directors. The following transitions on the board have been announced: Richard Kender, retired SVP of bu...
Richard Kender, retired SVP of Business Development and Corporate Licensing for Merck & Co., Inc., has been appointed to the Longeveron Board...